Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siMTA1
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, In Vitro
01
Overview
siMTA1 is a small interfering RNA (siRNA) designed to target and down-regulate the expression of Metastasis-associated protein 1 (MTA1), a protein linked to tumor progression, drug resistance, and poor prognosis in certain cancers, particularly luminal-b type breast cancer. Preclinical research demonstrates that knockdown of MTA1, either directly or via siMTA1-loaded exosomes, enhances sensitivity to the chemotherapy agent gemcitabine, reverses epithelial-mesenchymal transition (EMT), and inhibits autophagy, thereby promoting tumor growth inhibition and cell death in breast cancer models[1][2]. The approach leverages exosomes as vehicles for siRNA delivery to increase therapeutic specificity and reduce side effects.
- Other names
- siMTA1-loaded exosomessiMTA-1-loaded exosomessiMTA 1-loaded exosomes
02
Targets
MTA1 (Metastasis-associated protein 1)
Beyond the preview
Go deeper on siMTA1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siMTA1.